Comparative Pharmacology
Head-to-head clinical analysis: E Z HD versus E Z PAQUE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E Z HD versus E Z PAQUE.
E-Z-HD vs E-Z-PAQUE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
E-Z-HD is a barium sulfate contrast agent that acts by coating the mucosal surface of the gastrointestinal tract, providing radiographic contrast due to its high atomic number, which attenuates X-rays.
E-Z-PAQUE (barium sulfate) is a radiocontrast agent that attenuates X-rays, providing negative contrast enhancement of the gastrointestinal tract. It works by coating the mucosal surface and filling the lumen, allowing visualization of anatomical structures and pathology.
Barium sulfate suspension, 60-120 mL (30-100% w/v) orally for single or double-contrast upper GI studies; for lower GI studies, 500-1500 mL (10-20% w/v) as enema.
Oral or rectal administration: 300-600 mL of a 1% to 2% suspension (10-20 g barium sulfate) for upper GI series; 750-1500 mL of a 15% to 25% suspension (113-375 g barium sulfate) for lower GI series, given as a single dose.
None Documented
None Documented
Not applicable (non-absorbed, local GI agent; negligible systemic absorption)
Not applicable; barium sulfate is not systemically absorbed, so no plasma half-life exists. The gastrointestinal transit half-life is approximately 1-2 hours, depending on motility.
Renal: 0%; Biliary/Fecal: 100% (eliminated unchanged in feces as insoluble barium sulfate)
E-Z-PAQUE (barium sulfate) is not absorbed; elimination is entirely fecal, with 100% of the administered dose excreted unchanged in feces within 24-48 hours. No renal or biliary excretion occurs.
Category C
Category C
Barium Sulfate Contrast Agent
Barium Sulfate Contrast Agent